Archive

Archive for May, 2009

نسألكم الدعاء

May 29, 2009 shimaasherif 2 comments

السلام عليكم ورحمة الله وبركاته

اعتذر عن كتابة مواضيع جديدة هذه الفترة وذلك لظروف الامتحانات

 

exaaaaaaaaaaaams

نسألكم الدعاء بالتوفيق

ملف باوربوينت بعنوان Targeted Nano Carriers For Anti cancer drugs

 

Powerpoint file about

Targeted Nano Carriers For Anti cancer drugs

Made for pharmaceutics subject

By

Nano Team

Download Link  للتحميل

 

http://rapidshare.com/files/233426420/nanocarriers.rar

 

 

اللهـــــــــم إني أســـــــــــألك …

اللهم إني أسألك رحمة من عندك

 تهدي بها قلبي

وتجمع بها أمري

 وتلمّ بها شعثي

وترفع بها شاهدي

 وتحفظ بها غائبي

 وتبيّض بها وجهي

وتزكّي بها عملي

 وتلهمني بها رشدي

وتعصمني بها من كلّ سوء

 

اللهمّ إني أسألك رحمة من عندك

 أنال بها شرف كرامتك في الدنيا والآخرة

 

اللهم ذا الأمر الرشيد والحبل الشديد أسألك الأمن يوم الوعيد

والجنة يوم الخلود مع المقرّبين الشهود

 إنك رحيم ودود فعّال لما تريد

أبحــــــــــاث الملتقى العلمي الســـــــــابع بالاسكندرية

May 14, 2009 shimaasherif 3 comments

Disposal of pharmaceutical and personal care products (PPCPs) powerpoint file

ملف باور بوينت عن

 Disposal of pharmaceutical and personal care products

For Pharmaceutics Subject

By Anti Waste Team

Download

http://rapidshare.com/files/232662449/new_ppcps.rar

or

http://asapload.com/222560

 

Afinitor New FDA Approaval …

 Afinitor

Generic Name: everolimus

Company: Novartis

The US Food and Drug Administration (FDA) has approved Afinitor (everolimus) tablets for patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib

Approaved in 31-3-2009

 Afinitor is the first oral, daily therapy (5 mg and 10 mg tablets) to treat advanced kidney cancer after failure of treatment with sunitinib or sorafenib. In cancer cells, Afinitor continuously targets mTOR, a protein that acts as a central regulator of tumor cell division, blood vessel growth and cell metabolism.

Afinitor is also being studied in multiple cancer types, including neuroendocrine, breast, gastric and hepatocellular carcinoma (HCC), as well as tuberous sclerosis complex (TSC) and non-Hodgkin’s lymphoma11. The active ingredient in Afinitor is everolimus, which is available in different dosage strengths under the trade name Certican® for the prevention of organ rejection in heart and kidney transplant recipients.

The chemical name of everolimus is

(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18- dihydroxy-12-{(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[30.3.1.04,9]hexatriaconta-16,24, 26,28-tetraene-2,3,10,14,20-pentaone.

The molecular formula is C53H83NO14 and the molecular weight is 958.2. The structural formula is

MECHANISM OF ACTION

Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt‑1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.

Read more…

Towards Drugs of the Future

future

edition 2009 | PDF | 130 pages | 2.88 mb

The scope of this book is that the pharmaceutical industry must change the way it operates. The editors of this book feel that the current business model is economically unsustainable and incapable to meet expectations of modern society. The number of novel medications in the global industry pipeline is insufficient to suffice demand of the markets, the financial performance of several companies is declining, sales and marketing costs are rising, regulatory constraints are increasingly challenging and overall reputation of industry is tarnishing. Unmet medical needs must be better addressed and tangible benefits need to be exposed in order to be rewarded by healthcare payers. In addition, the focus is shifting from simple treatment of the ill to preventative measures and health management. This volume addresses newest development in synthetic and medicinal chemistry with the emphasis on global challenges. One of the goals is to ensure that new chemistry develops novel technologies in which system biology approach or target approach is computer simulated, testing is performed in silico on rat or human digital models and synthesis of molecules is restricted to intelligent synthesis of treatments based on simulations. Implementation of such new technologies requires the pharmaceutical industry to rethink and adopt the current business model in order to contribute value to the healthcare systems of the future.

Download

http://www.megaupload.com/?d=6FQRRIQH

Antimicrobial Resistance and Implications for the 21st Century كتاب

21

408 pages | PDF | 3,2 MB

Antimicrobial resistance can develop in any type of microbe (germ). Microbes can develop resistance to specific medicines. A common misconception is that a persons body becomes resistant to specific drugs. However, it is microbes, not people that become resistant to the drugs. Drug resistance happens when microbes develop ways to survive the use of medicines meant to kill or weaken them. If a microbe is resistant to many drugs, treating the infections it causes can become difficult or even impossible. Someone with an infection that is resistant to a certain medicine can pass that resistant infection to another person. In this way, a hard-to-treat illness can be spread from person to person. In some cases, the illness can lead to serious disability or even death.

This comprehensive, up-to-date volume aims to define issues and potential solutions to the challenges of antimicrobial resistance. The chapter authors are leading international experts on antimicrobial resistance among a variety of bacteria (Streptococcus pneumoniae, enteroccoci, staphylococci, gram-negative bacilli, mycobacteria species) viruses (HIV, herpesviruses), parasites (malaria, leishmaniasis) and fungi (Candida species, fusarium etc.). The chapters will explore the molecular mechanisms of drug resistance, the immunology and epidemiology of resistance strains, clinical implications and implications on research and lack thereof, and prevention and future directions. This volume will also describe the steps that researchers are taking to develop molecular methods for detecting resistance; develop drugs and other means to deal with newly-resistant organisms. A special chapter to address the issues on strategies to limit antimicrobial resistance propagation will be included in this volume.

 

Download

http://www.megaupload.com/?d=LQFN0XFA

 

أبحاث فارماكولوجي باللغة العربية … موقع مميز

 

لو مطلوب منك بحث عن أحد المواضيع التالية باللغة العربية

مثبطات الجملة العصبية المركزية C.N.S Depressant

منبهات الجملة العصبية المركزية CNS Stimulants

أدوية التخدير العام General Anesthetics والموضعي

الأدوية المؤثرة في العضلات الهيكلية

مسكنات الألم

أدوية التوجيه النفسي Psychotropic Drugs or Antipsychopharmacology

الأدوية المؤثرة في الجهاز العصبي المركزي

 

يمكنك زيارة الموقع التالي

http://www.mbjabri.8k.com/pharmarabia/index.htm

 

هكذا علمتني الحيــــــــــــاة

May 9, 2009 shimaasherif 2 comments

life 

علمتني الحياة

 أن،، اودع من أحب،، في صمت …

وعلمتني أن أجامل من اكره من اجل من احب

 …وعلمتني الصمت ساعة الغضب كي لأخسر الموقف

علمتني الحياة

 أن أحذر من صديقي أكثر من عدوي فقد يكون خصمي في يوم

 وعلمتني أن لا أسلم قلبي للحب كاملاً فقد يموت النصف العاشق

…ويبقى لي النصف الأخر نابض بالحياة

علمتني الحياة

 أن الوفاء عمله نادرة ولكن ليس صعب الحصول عليه

 …وعلمتني أن السفر الطويل يعلم الصبر ولكن لينسى الغدر

 وعلمتني أن النوم لحظات بسعادة خير من النوم ساعات بلا هدف

 

علمتني الحياة

 أن أحيى على ضوء شمعة بضمير أشرف …من أن أحيا بلا ضمير تحت أضواء قصر

 …وعلمتني أن الشباب قوة إذا تحكم العقل به وضعف إذا تبع جنونه

 علمتني الحياة

أن الفشل دائما هوا بداية كل نجاح

 وعلمتني أن الخسارة تعلم المكسب

Read more…